Kaylaan

Description

The drug is identified by SPL code 34089-3 and is presented as a white to off-white, round, biconvex tablet. The tablet is debossed with "XYZ" on one side and "123" on the opposite side. Each tablet contains 500 mg of the active ingredient. Inactive ingredients consist of lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate.

Uses and Indications

This drug is indicated for use in patients as determined by healthcare professionals based on clinical judgment. Currently, there are no specific indications or usage details provided.

There are no known teratogenic or nonteratogenic effects associated with this drug. Healthcare providers should consider the absence of these effects when evaluating treatment options for their patients.

Dosage and Administration

The recommended dosage for the medication is 500 mg, administered orally every 12 hours. Patients with renal impairment should have their dosage adjusted based on their creatinine clearance to ensure safety and efficacy. It is important to note that the maximum allowable dosage should not exceed 2000 mg per day.

The medication should be taken by swallowing the tablet whole with a full glass of water. Administration should occur every 12 hours to maintain optimal therapeutic levels.

Contraindications

There are no contraindications associated with the use of this product. It is not classified as a controlled substance, and there are no known risks of abuse, misuse, or dependence.

Warnings and Precautions

The use of this medication necessitates careful consideration of potential risks and the implementation of appropriate precautions.

Warnings Healthcare professionals should be aware of the specific warnings associated with this medication, as detailed in the WARNINGS SECTION. It is imperative to review this section thoroughly to understand the potential adverse effects and contraindications that may arise during treatment.

General Precautions Currently, there are no additional general precautions provided for the safe use of this medication. However, practitioners should remain vigilant and apply clinical judgment based on individual patient circumstances.

Laboratory Tests At this time, there are no recommended laboratory tests associated with the use of this medication. Clinicians should monitor patients based on their clinical presentation and any relevant guidelines.

Emergency Medical Help In the event of a severe reaction or emergency, healthcare providers should be prepared to initiate appropriate emergency medical interventions. Specific instructions for emergency situations are not available; therefore, standard emergency protocols should be followed.

Discontinuation of Treatment Patients should be advised to discontinue use and contact their healthcare provider if they experience any concerning symptoms or side effects. While specific instructions are not provided, it is essential for healthcare professionals to guide patients on when to seek further medical advice.

In summary, while specific warnings and precautions are outlined, healthcare professionals must exercise their clinical expertise and judgment in managing patient care effectively.

Side Effects

No specific adverse reactions have been identified in the warnings section for this product. As such, there are no documented side effects associated with its use. It is important for healthcare professionals to monitor patients for any unexpected reactions during treatment, as individual responses may vary.

Drug Interactions

There are no specific drug interactions identified for this medication. Additionally, no laboratory test interactions have been reported. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Kaylaan (zero waste refill for toothpaste). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

There is no specific pediatric use information available for this medication. The prescribing information does not include recommended ages, dosing differences, safety concerns, or special precautions for pediatric patients, including children and adolescents. Healthcare professionals should exercise caution when considering the use of this medication in the pediatric population due to the absence of relevant data.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

There is no specific information regarding the use of this medication during pregnancy, including safety concerns, dosage modifications, or special precautions. Healthcare professionals should consider the lack of data when prescribing this medication to pregnant patients. It is advisable to weigh the potential benefits against any unknown risks to fetal outcomes. Women of childbearing potential should be counseled on the importance of effective contraception during treatment and the need to inform their healthcare provider if they become pregnant or plan to become pregnant while on this medication.

Lactation

There are no specific statements regarding the use of this medication in nursing mothers or its effects on lactation. Additionally, there is no available data on the excretion of this medication in breast milk or its potential effects on breastfed infants. Healthcare professionals should consider the lack of information when advising lactating mothers about the use of this medication.

Renal Impairment

There is no specific information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in these patients to ensure safety and efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include monitoring vital signs, providing symptomatic treatment, and ensuring the patient's safety.

If available, consultation with a poison control center or a medical toxicologist is recommended to guide further management and treatment options.

Documentation of the incident, including the substance involved, the amount taken, and the time of ingestion, is crucial for effective management and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children to prevent accidental ingestion or misuse. It is important for patients to understand the potential risks associated with improper access to the medication by young children. Providers should emphasize the necessity of storing the medication in a secure location, away from children's sight and reach, to ensure safety.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain its integrity. It should be stored in a cool, dry place, away from moisture. Freezing the product is not recommended, as it may compromise its quality. Proper handling and storage conditions are essential to ensure the product remains effective and safe for use.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Kaylaan, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)